Abstract: The present invention relates to conjugates comprising crosslinked hyaluronic acid to which a plurality of drug moieties are covalently and reversibly conjugated, wherein the hyaluronic acid exhibits a certain degree of modification and comprises degradable crosslinked moieties. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.

Abstract: The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety —Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each —X0D— is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.

Abstract: The present invention relates to conjugates comprising backbone moieties that are crosslinked via particular crosslinker moieties to which a plurality of drug moieties are covalently and reversibly conjugated. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases.

Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.

Abstract: A method for unloading a payload at a loading station includes selecting the payload to be unloaded from different payloads and registering a total target quantity of the selected payload to be unloaded at the loading station as a target quantity unit, a current total quantity of the selected payload that has already been unloaded at the loading station as an actual quantity unit, a number of already performed unloading procedures corresponding to a quantity of the selected payload that has already been unloaded at the loading station, or a difference between the target quantity unit and the actual quantity unit.

Abstract: A method for tipping out a cargo load from a reception unit includes providing the reception unit on a lifting device of a work machine, performing a tipping out process of a mass of cargo load from the reception unit, detecting a predetermined residual mass of the cargo load remaining in the reception unit, detecting a predetermined loading mass tipped out during the tipping step, and completing the tipping out process as a function of the predetermined residual mass or the predetermined loading mass.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.

Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.

Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.

Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.

Abstract: The present invention relates to a displacement sensor for contactlessly measuring a position of a magnet relative to a reference point. The displacement sensor comprises the magnet which can be displaced along a movement axis, a plurality of magnetic field sensors which are arranged in series and which are arranged parallel with the movement axis of the magnet and a calculation unit for forming a position signal which indicates the position of the magnet relative to the reference point. The plurality of magnetic field sensors which are arranged in series are arranged in such a manner that the displacement measurement ranges of adjacent magnetic field sensors overlap in an overlap range.

Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.

Abstract: The present invention relates to a displacement sensor for contactlessly measuring a position of a magnet relative to a reference point. The displacement sensor comprises the magnet which can be displaced along a movement axis, a plurality of magnetic field sensors which are arranged in series and which are arranged parallel with the movement axis of the magnet and a calculation unit for forming a position signal which indicates the position of the magnet relative to the reference point. The plurality of magnetic field sensors which are arranged in series are arranged in such a manner that the displacement measurement ranges of adjacent magnetic field sensors overlap in an overlap range.